Description

Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver.

Investigational Activity

Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal lung disease characterized by inflammation and scarring of the lungs.

Pirfenidone for treatment of patients with IPF has been studied in multiple Phase 2 and three Phase 3 clinical trials. InterMune has completed a 779-patient Phase 3 program in patients with IPF (CAPACITY) and a New Drug Application (NDA) has been accepted for Priority Review by the FDA.

Investigational, not an FDA approved product.